Related Experiment Video
Updated: May 12, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Janus kinase inhibitors in autoimmune diseases
John J O'Shea1, Apostolos Kontzias, Kunihiro Yamaoka
1Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892-1930, USA. osheajo@mail.nih.gov
None:
Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases or Jaks are critical for a large family of cytokines and the first Jak inhibitors has been approved by the FDA. It is therefore timely to consider this new category of drugs and reflect on their potential roles, present and future, in the treatment of RA and related disorders.
Related Concept Videos
The JAK-STAT Signaling Pathway
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
cAMP-dependent Protein Kinase Pathways
PI3K/mTOR/AKT Signaling Pathway
Inhibitors of Viral Protein Synthesis
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
